News
12-10-2012, 02:13 AM
Genentech, a member of the Roche Group, today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo.
More... (http://www.news-medical.net/news/20121210/New-survival-results-from-Genenteche28099s-Perjeta-Phase-III-combination-study-on-HER2-positive-mBC.aspx)
More... (http://www.news-medical.net/news/20121210/New-survival-results-from-Genenteche28099s-Perjeta-Phase-III-combination-study-on-HER2-positive-mBC.aspx)